UL Solutions' $350M Worldly Deal Shows Data and Compliance Assets Joining the Dealmaking Mix
UL Solutions' purchase of Worldly, holder of exclusive Higg Index marketing rights, sits outside pharma but echoes a week of small-cap consolidation and capability-led deals in the sector.
What happened
UL Solutions has agreed to acquire Worldly Holdings in a deal of roughly $350M. Worldly is a supply chain software company and holds exclusive marketing rights to the Higg Index. The testing and certification group will also repurchase $130M of Class B shares. The material does not say how that repurchase relates to the $350M headline figure, whether it is included or additional, so readers should wait for the deal documents before comparing the numbers.
The deal is not a pharmaceutical transaction, and CompePharma's readers should treat it as a read-across rather than a sector event. Its interest is in what the buyer is paying for: a software platform and a controlled index, not a product or a plant.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Sources
- UL Solutions to acquire supply chain software firm Worldly in roughly $350M deal UL Solutions Inc. · 17 Nov 2026
- Gedeon Richter to acquire Mayne Pharma in AUD 604 million cash deal Gedeon Richter · 16 Nov 2026
- Aytu BioPharma to be acquired by Rosemont for about $56M as EXXUA sales grow Aytu Biopharma, Inc · 16 Nov 2026
- Merck KGaA to acquire Rapid Micro Biosystems in $0.75-per-share cash tender offer Rapid Micro Biosystems, Inc. · 16 Nov 2026
- ENDRA reports Q3 net loss of $1.5m as Noble Africa merger awaits closing conditions ENDRA Life Sciences Inc. · 16 Nov 2026
Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. It can contain errors; check the sources. Not investment advice.
Retension's $51.75M IPO buys a Phase 2b readout, but trial costs will set the clock
Retension's first earnings report since its upsized October IPO shows a $5.9M quarterly loss and a single catalyst: RTN-001 Phase 2b data in H1 2027. Peers show how thin other routes to capital are.
Insight Molecular's $15M raise shows how thin the small-cap diagnostics funding market is
IMDX's $1.75-per-share offering, with pre-funded warrants and a transplantation R&D pitch, sits at the small end of a financing spectrum that runs from a $51.75M IPO to royalty sales.
Kyntra's prostate exit shows how thin the funding runway is for a biotech that has to reset
After a Phase 2 interim miss, Kyntra Bio is cutting its royalty-financing cap and pivoting to roxadustat in MDS, and its plan is subject to funding in a split biotech capital market.